Transarterial embolisation of a large focal nodular hyperplasia, using microspheres, in a paediatric patient by Oliveira, C et al.
CASE REPORT
Transarterial embolisation of a large focal nodular
hyperplasia, using microspheres, in a paediatric
patient
















Accepted 28 June 2015
To cite: Oliveira C, Gil-
Agostinho A, Gonçalves I,
et al. BMJ Case Rep
Published online: [please




Benign liver tumours are uncommon in children,
haemangiomas being the most frequent. Focal nodular
hyperplasia (FNH) represents about 2% of paediatric
liver tumours. In children, as in adults, a conservative
approach is generally recommended. However, large
lesions (greater than 5 cm) are more frequent in the
paediatric age group, and in these cases, as well as in
growing lesions, surgical removal may be advised.
Transarterial embolisation (TAE) has been a successful
alternative option described in older patients, especially
in cases where surgical removal is not possible. This
minimally invasive procedure may also become an option
in the paediatric group. The authors report the case of a
boy with a large FNH treated with TAE using
microspheres.
BACKGROUND
Focal nodular hyperplasia (FNH) is a rare entity in
children, and few cases have been reported in the
literature. Transarterial embolisation (TAE) is a suc-
cessful alternative to resection and has been
described in adult patients.
CASE PRESENTATION
A 15-year-old boy was referred to our department
due to the incidental ﬁnding of a liver nodule: a
hypoechoic focal liver lesion measuring 6 cm at
initial presentation (the patient was regularly fol-
lowed with a yearly ultrasound (US) scan, since the
age of 4, due to kidney stones). An outside MRI
study was performed and atypical haemangioma
was the initial reported diagnosis at the age of 14.
INVESTIGATIONS
In our institution, a new MRI study using
hepato-speciﬁc contrast agent (gadoxetic acid), dis-
closed a larger lesion (18 cm at long axis) with
imaging features suggesting FNH diagnosis (ﬁgure 1).
Brain MRI, physical examination as well as laboratory
data, including tumoural markers (α-fetoprotein
(AFP) and CA19.9), and hormonal studies and carbo-
hydrate deﬁcient transferrin (CDT) were normal.
DIFFERENTIAL DIAGNOSIS
An FNH lesion consists of well-differentiated hepa-
tocytes forming nodules subdivided by ﬁbrous
septa, devoid of a ﬁbrous capsule. The central stel-
late scar contains abnormal arterial vessels without
accompanying portal veins. Ductular reaction is
usually present at the interface between hepatocytes
and ﬁbrous bands, and is highly suggestive of FNH
diagnosis.
At the paediatric age, most FNHs are incidental
ﬁndings; but some predisposing factors have been
described. Vascular abnormalities with portal ﬂow
deprivation due to congenital or surgical porto-
systemic shunts, previous chemotherapy or radio-
therapy (due to possible vascular injury) and Kasai
procedure for biliary atresia, have all been impli-
cated as risk factors for FNH and nodular regen-
erative hyperplasia (NRH) development.1–4
There are no speciﬁc clinical manifestations for
FNH in children. The majority of the cases are dis-
covered fortuitously for unrelated reasons, as in the
presented case. Only one-third of cases are symp-
tomatic, mainly large lesions. The most frequent
symptoms are abdominal pain, weight loss and
weakness, sometimes in association with a palpable
abdominal mass. Tumour rupture and haemorrhage
Figure 1 Large hepatic lesion in a young male patient. (A) Ultrasound showing a slightly hypoechoic lesion in the
right hepatic lobe; (B) T2-weighted MRI revealing a slightly hyperintense lobulated mass with two central areas of
higher signal (asterisks)—central scars. (C) T1-weighted subtraction MRI before and after gadolinium in arterial phase
revealing intense nodular enhancement; in the venous phase the lesion was isointense with the surrounding
parenchyma. Imaging features suggested a focal nodular hyperplasia diagnosis.
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are rare events. Laboratory tests including tumour marker AFP
do not show abnormal values.2 5
FNH imaging features are similar in adults and children.
Compared to the surrounding nodule, the central scar is hypo-
dense or isodense on pre-contrast CT images. After contrast, the
central scar is usually hypodense in the arterial phase. This last
feature has been more common in paediatric cases of FNH, which
could be explained by the larger diameter of the lesions.1–6
However, in patients undergoing post-malignancy treatment,
FNH-like nodules are usually multiple and smaller in size; a
central scar may be difﬁcult to identify even on MRI study.3 6
Enhancement after gadolinium injection is similar to that
observed on a CTscan. Liver MRI using a hepato-speciﬁc contrast
agent may show, on delayed hepatocyte phase images, contrast
uptake retention due to the presence of normal quantity and func-
tion of organic anionic transporter protein (OATP) 3 receptors at
the sinusoidal pole of the hepatocyte, and no excretion due to the
lack of normal excretory bile ducts. However, similar behaviour
has also been described in well and even moderately differentiated
hepatocellular carcinoma, at least in the adult population.7 8 In the
presented case, no signiﬁcant contrast retention was noted. The
use of superparamagnetic iron oxide-enhanced MRI has also been
reported in the literature, as a useful method to differentiate FNH
in children,9 but it is no longer commercially available.
Fibrolamellar hepatocarcinoma is an important differential
diagnosis as it frequently presents an area of scarring, usually
hypointense on T2-weighted images. Features favouring ﬁbrola-
mellar hepatocarcinoma are the presence of intratumoural calciﬁ-
cations, large size of the central scar, heterogeneity and
concomitant presence of lymphadenopathies and/or other metas-
tases.2 6 10 Hepatic adenoma, especially of the non-steatotic sub-
types, may possess some imaging features similar to FNH, but
the central scar is less frequent, and associated with less vivid
enhancement in the arterial phase and hypointensity in the
delayed hepato-speciﬁc phase.11 No contrast retention is
observed after hepato-speciﬁc contrast in the hepatobiliary phase.
Hepatoblastoma usually occurs in younger children and presents
as a more heterogeneous and bulky mass.12 Regenerative hepatic
nodule (NRH) is also a rare entity in children and usually consists
of diffuse micronodular transformation, but it may appear as a
focal nodule; the differential feature in this case is the absence of
strong arterial enhancement.1 In adults, due to the high speciﬁ-
city of CTand MRI in diagnosing FNH, there is usually no indi-
cation for biopsy in the presence of typical radiological
features.13 In children, there is no study validating these criteria.
Multiple or larger lesions are also more common in children than
in adults, and imaging features are atypical in at least two-thirds
of cases.1–3 In these cases, biopsy of the mass and the non-
tumoural liver are performed to assess the diagnosis and
rule-out-associated abnormalities of the liver.
In our case, due to the large size (more than 10 cm) of the
lesion and its growing pattern, a US-guided biopsy was per-
formed. Histological analysis showed features supporting FNH
diagnosis: normal hepatocytes in a trabecular disposition,
ﬁbrous septa, ductular reaction and inﬂammatory inﬁltrate;
large dysplastic arterial vessels were found. Surrounding liver
parenchyma was normal.
TREATMENT
A conservative ‘wait-and-see’ approach was decided on.
A 3-month control MRI study showed a mild increase in the
lesion’s size (18–19 cm at long axis) (ﬁgure 2). At this point, the
patient had abdominal discomfort and a palpable abdominal
mass, so management was reviewed. A very large surgical
Figure 3 Selective angiographic study showing the two hepatic nodular areas fed by large arterial branches (A and B). Control after transarterial
embolisation showing signiﬁcant decrease in the vascular ﬂow (C).
Figure 2 T2-weighted (A) and
T1-weighted MRI with fat saturation
after hepato-speciﬁc contrast agent in
the hepatobiliary phase (B). There is a
mild enlargement of the lesion; and
similar enhancement to the
surrounding parenchyma.
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resection was necessary to remove the entire lesion, so a TAE was
proposed. Selective angiographic study revealed two large arter-
ial feeding vessels nourishing the lesion. The larger area was fed
by an arterial branch of the celiac trunk and a smaller portion of
the tumour was fed by superior mesenteric arterial branches. An
aortogram was also performed and no other signiﬁcant arterial
feeders were noted. After subsegmental catheterisation, TAE was
performed using microspheres of 300–500 mm (ﬁgure 3). A total
of 6 mL of microspheres diluted in 40 mL of saline solution and
2 mL of iodine contrast media were used.
OUTCOME AND FOLLOW-UP
No complications were registered after the procedure. A control
MRI study performed 3 months later revealed no signiﬁcant
change in size of the lesion, but only a slight decreased enhance-
ment in the arterial phase, especially in the more anterior area
(ﬁgure 4). A second TAE using microspheres (300–500 mm) was
subsequently performed 5 months later (ﬁgure 5). In order to
reduce it further, arterial feeding of the lesion, a more
aggressive approach, was performed in the second procedure. A
total of 18 mL of microspheres diluted in saline solution and
iodine contrast media were used, until complete nodule embol-
isation was visually achieved. After the second TAE procedure,
the patient developed a transitory postembolisation syndrome
with fever and analytic impairment, with full recovery, and was
discharged from the hospital on day 7.
After 3 months, a new follow-up MRI study was performed,
which showed a signiﬁcant size reduction of the tumour (from
19 to 13 cm at its large axis) and which also showed reduced
arterial enhancement. Some non-enhancing areas due to necro-
sis were also noted (ﬁgure 6). The patient’s clinical symptoms
reduced considerably.
DISCUSSION
Paediatric FNH is a rare entity, representing 2–7% of paediatric
liver tumours, and may occur in all paediatric age groups, with
no gender dominance.1 2
Since FNH is a slow-growing tumour, without known malig-
nant transformation, and is rarely complicated with haemor-
rhage or rupture; a conservative strategy is advised for
asymptomatic children. Surgical resection is usually recom-
mended for symptomatic paediatric patients, patients with
increasing size of FNH, or patients in whom malignancy cannot
be rule out conﬁdently.5 14
The natural history of these tumours is poorly known in chil-
dren. Some cases of spontaneous regression have been
described. Recurrence of FHN after surgery has also been
reported in the literature.2 6
Cases associated with vascular disorder due to portal depriv-
ation may beneﬁt from restoration of the portal ﬂow, leading to
involution of the FNH.2 6 15 However, hepatoportal sclerosis
would contraindicate the closure of the shunt. A case of a wide-
spread FNH invading the whole liver, treated with transplant-
ation, has also been reported.16
TAE is described in adults as a successful treatment option,
with improvement of symptoms, signiﬁcant decrease on size and
even total involution of the lesion.17 18 Few paediatric cases of
FNH embolisation are reported in the literature and none
reported using microspheres.14 19 20 We present a successful
case of signiﬁcant reducing of a large FNH lesion after TAE
using microspheres, with no major complications.
More cases must be reported to evaluate the outcome of the
procedure, and to assure its safety in the paediatric age group.
Meanwhile, from the authors’ point of view, TAE is a valid
secure, minimally invasive and efﬁcient procedure in the
Figure 4 T2-weighted (A) and
T1-weighted MRI with fat saturation
after gadolinium in the arterial phase
(B). No signiﬁcant decrease in the
lesion size was noted, but after
gadolinium, there was signiﬁcant
reduction in the arterial enhancement,
especially in the more anterior portion.
Figure 5 Selective angiographic study of one of the hepatic nodular
areas after transarterial embolisation, showing absent arterial ﬂow.
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treatment of large and growing FNH lesions in the paediatric
age group.
Learning points
▸ Paediatric focal nodular hyperplasia (FNH) is a rare entity,
representing 2–7% of paediatric liver tumours.
▸ Differential diagnosis includes ﬁbrolamellar carcinoma,
hepatic adenoma, hepatoblastoma and well-differentiated
hepatocarcinoma.
▸ Surgical removal is recommended in large and/or in growing
lesions; otherwise, a conservative approach is indicated.
▸ Transarterial embolisation may be considered as an efﬁcient
procedure in the treatment of large and growing FNH
lesions, even in the paediatric age group, when surgical
removal is not advised.
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Figure 6 T2-weighted (A) and
T1-weighted MRI with fat suppression
after gadolinium in the arterial phase
(B). There is signiﬁcant decrease in the
lesion size.
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